This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kosaki, R. Articles by Yamaguchi, Y. Search for Related Content PubMed PubMed Citation Articles by Kosaki, R. Articles by Yamaguchi, Y.

Overproduction of Hyaluronan by Expression of the Hyaluronan Synthase Has2 Enhances Anchorage-independent Growth and Tumorigenicity¹

The Burnham Institute, La Jolla, California 92037

	ABSTRACT

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS HA Production in Transfected... Adhesion and Growth in... Overproduction of HA Makes... HA Overproduction Increases... DISCUSSION REFERENCES

 
Hyaluronan (HA) has long been implicated in malignant transformation and tumor progression. However, due to the lack of molecular tools to directly manipulate production of HA, which does not require a core protein for its synthesis, our understanding of the role of HA in tumor cells has been largely circumstantial. In this study, we genetically manipulated the production of HA by transfection of a mammalian HA synthase Has2 into human HT1080 cells and examined the malignant phenotype of transfected cells. We found that increased production of HA promotes anchorage-independent growth and tumorigenicity of the cells. Has2-transfected cells formed greater numbers of colonies in semisolid medium. Tumors in nude mice derived from Has2-transfected cells grew more rapidly and were 2–4 times larger than those derived from control cells at termination of experiments. Histological and biochemical analyses of tumors revealed no significant differences in cell density and tissue structures between them, indicating that the larger size of the tumors was due to enhanced cell proliferation, not to increased accumulation of tumor stroma or increased angiogenesis. These results demonstrate that HA production by tumor cells per se promotes proliferation of these cells in tissues and provides direct evidence for the role of HA in tumorigenicity.

	INTRODUCTION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS HA Production in Transfected... Adhesion and Growth in... Overproduction of HA Makes... HA Overproduction Increases... DISCUSSION REFERENCES

 
The ECM⁴ is one of the crucial environmental elements that affects tumor cell behavior. ECM serves as a scaffold to which tumor cells adhere and migrate. ECM is also thought to act as a reservoir of growth factors and cytokines that are potentially beneficial to malignant cells (1) . HA is a large glycosaminoglycan containing repeating disaccharide units of N-acetylglucosamine and glucuronic acid residues. Several studies have shown that HA plays significant roles in matrix assembly, cell proliferation, and migration (2, 3, 4, 5) . Spatiotemporal distribution of HA during embryogenesis and wound healing indicates that HA plays important roles in tissue remodeling processes (6 , 7) .

There is increasing evidence that HA plays significant roles in tumor progression (8, 9, 10, 11) . HA is present in a greater amounts in a variety of tumor tissues than in normal counterparts, including colon cancer (12) , breast cancer (13, 14, 15) , glioma (16) , lung carcinoma (17) , and Wilm’s tumor (18) . It has also been shown that high HA production correlates with invasive and metastatic activities of tumors (19, 20, 21, 22, 23) . HA is also implicated in tumor angiogenesis (9) . These observations suggest that increased levels of HA may provide an environment facilitating various aspects of tumor progression.

Despite this wealth of data, whether increased cellular HA production has direct effects on tumor cell proliferation has not been addressed because HA, which does not contain any protein components, cannot be directly manipulated by molecular biological techniques. Cloning of mammalian HA synthases by our and other laboratories now allows genetic manipulation of the cellular HA production. Here, we show that increased production of HA directed by human HA synthase Has2 (24) promotes anchorage-independent growth and tumorigenicity of human HT1080 cells. These changes toward a more malignant phenotype did not, however, accompany increased growth rate of cells in monolayers, suggesting that the HA exerts its growth-promoting effect mainly in a three dimensional environment. These results provide the first evidence for a direct relationship between cell-autonomous HA production and malignant transformation.

	MATERIALS AND METHODS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS HA Production in Transfected... Adhesion and Growth in... Overproduction of HA Makes... HA Overproduction Increases... DISCUSSION REFERENCES

 
Materials.
The CellPhect transfection kit and the HA Test HA assay kit were purchased from Pharmacia (Piscataway, NJ). Polyclonal antihuman factor VIII antibody and MU were obtained from Sigma Chemical Co. (St. Louis, MO). BCA Protein Assay Reagent kit and Vectastain ABC kit were purchased from Pierce (Rockford, IL) and Vector Laboratories (Burlingame, CA), respectively. Monoclonal antibody 12CA1 against the influenza virus hemagglutinin epitope was purchased from Boehringer Mannheim (Indianapolis, IN). Type I collagen was purchased from Collagen Corp. (Palo Alto, CA), and bovine plasma fibronectin was a kind gift from Dr. E. Ruoslahti (The Burnham Institute, La Jolla, CA).

Stable Transfectants.
A human fibrosarcoma cell line HT1080 was obtained from American Type Culture Collection (Manassas, VA) and maintained in MEM supplemented with 10% FCS, 2 mM glutamine, 100 unit/ml penicillin, and 100 µg/ml streptomycin (growth medium). For isolation of stable transfectants, subconfluent cultures of HT1080 cells in 10-cm culture dishes were transfected with 10 mg of pHAStagC or an insertless pcDNA3 using the CellPhect transfection kit and selected in the presence of 500 µg/ml G418. pHAStagC contains a full-length human Has2 cDNA tagged with the influenza hemagglutinin epitope sequence at its COOH terminus (24) . From each transfection experiment, 10 G418-resistant colonies were picked with cloning rings. The expression of Has2 was examined by immunoblotting with 12CA1 antibody against the influenza hemagglutinin epitope, as described previously (24) . Three Has2 transfectant clones and two control clones were randomly selected for these studies.

Assay of HA Production.
The HA production of transfectant clones into culture supernatants was measured by the Pharmacia HA Test as described previously (24) . Briefly, 1 x 10⁵ cells were plated in a 35-mm wells in growth medium. Eighteen h after plating, cells were fed with fresh medium and cultured for another 24 h, and their culture supernatants were collected for HA assay. For inhibition of HA production, cells were pretreated with 0.05 mM or 0.1 mM MU for 3 days before the assay. MU was dissolved in small volumes of DMSO and added to culture medium. The final concentration of DMSO was 0.1%. Pretreated cells were then used in the standard HA production assay in the presence of MU. Control cultures were treated with 0.1% DMSO only.

Adhesion Assays.
Wells of 96-well plates (non-tissue culture-treated; Flow Laboratories, McLean, VA) were coated with 10 µg/ml type I collagen or fibronectin at room temperature for 4 h. After washing, wells were blocked with 3 mg/ml BSA in PBS for 1 h. Cells (2.5 x 10⁴/well) suspended in MEM containing 1 mg/ml BSA were plated into each well and incubated under 5% CO₂ at 37°C for 30 min. Wells were gently washed twice with PBS to remove nonattached cells. Attached cells were fixed with methanol and stained with 0.5% toluidine blue in 3% formaldehyde for 1 h. After washing with PBS, stained cells were solubilized with 1% SDS in 0.3% NaOH, and the A₅₉₀ of each sample was measured on a spectrophotometer.

Growth in Monolayers.
Has2- and control-transfected HT1080 cells were plated in 35-mm wells of six-well culture plates at 5 x 10⁴ cells/well in the growth medium. Because plating efficiencies of all these transfectants were shown to be the same, no adjustment was made in terms of numbers of cells plated. At 1, 2, 3, and 4 days after plating, cells in triplicate wells were trypsinized and counted on a hemocytometer. For inhibition of HA synthesis, cells were pretreated with 0.1 mM MU-0.1% DMSO or 0.1% DMSO alone as described above, and the growth assay was performed in medium containing MU-DMSO or DMSO alone.

Anchorage Independence.
Has2- and control-transfected HT1080 cells were suspended in 2 ml of growth medium containing 0.4% (w/v) low melting temperature agarose and plated onto a layer of 0.53% agar prepared in growth medium in a 60-mm dish. Dishes in triplicate were incubated at 37°C under 5% CO₂, and the number of colonies consisting of more than 30 cells was determined for each dish at 10 days after plating. For inhibition of HA synthesis, cells were pretreated with 0.1 mM MU as described above and plated on agarose plates containing 0.1 mM MU. As a control, cells were pretreated with 0.1% DMSO only and tested on agarose plates containing 0.1% DMSO.

In Vivo Tumor Growth.
Six-week-old female BALB/c nu/nu mice were given bilateral s.c. injections of transfected and control cells in both flanks. Each injection consists of 2 x 10⁶ cells in 200 µl of PBS. Growth of the tumors was evaluated by calculating tumor volume from the width and length of palpable tumor according to the following formula: volume = (width)² x length/2 (25) . When the first sign of distress was observed in any mouse in the experiment (which usually occurred at 2–3 weeks after inoculation for Has2-transfected cells), all mice in the experiment were euthanized, and their tumors were excised for examination. Wet weight of tumor tissues free of attached nontumor tissues was measured immediately after excision. Some of the tumors were fixed in 4% paraformaldehyde and embedded in paraffin. Sections from these tissues were examined by H&E staining and by immunohistochemistry with anti-factor VIII antibody. Immunohistochemistry was performed with the ABC method as described previously (26) . For measurement of DNA content, tumor tissues were homogenized using a Polytron homogenizer, followed by sonication for 30 s, and DNA content was measured by the Hoechst 33258 method according to Labarca and Paigen (27) with salmon sperm DNA as a standard.

	RESULTS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS HA Production in Transfected... Adhesion and Growth in... Overproduction of HA Makes... HA Overproduction Increases... DISCUSSION REFERENCES

 
Transfection of Has2 cDNA into HT1080 Cells.
Human fibrosarcoma HT1080 cells were transfected with pHAStagC (24) , which is a pcDNA3-based expression vector containing human Has2 cDNA tagged with the influenza hemagglutinin sequence recognized by the 12CA5 monoclonal antibody (28) . After G418 selection, several resistant colonies were randomly isolated and established as stable cell lines. For generation of control cell lines, HT1080 cells were transfected with pcDNA3 without an insert. Here, two Has2-transfected cell lines (designated as Has2–1 and Has2–2) and two control cell lines (designated as Cont-1 and Cont-2) were used.

Expression of Has2 in transfectants was examined by immunoblotting with the 12CA5 monoclonal antibody, which recognizes the hemagglutinin tag attached to the COOH terminus of Has2. As shown in Fig. 1A , a M_r 75,000 band reactive to 12CA5 was detected in all Has2-transfected clones. We previously showed that, in transfected human 293 cells, the Has2 protein is present in both the membrane and soluble fractions (24) . This observation was also the case in HT1080 transfectants. Small quantities of Has2 were detected in the soluble fraction (Fig. 1A, Lanes 3 and 4) , whereas the majority of the protein was in the membrane fraction (Lanes 1 and 2).

View larger version (26K): [in this window] [in a new window] [Download PPT slide]   Fig. 1. Expression of Has2 and production of HA in HT1080 transfectants. A, expression of recombinant Has2 protein in transfectants. HT1080 cells were transfected with pHAStagC, and stable transfectants were established after selection with G418. Membrane (Lanes 1 and 2) and cytosolic (Lanes 3 and 4) fractions were prepared from transfectants and immunoblotted with antihemagglutinin monoclonal antibody 12CA5 as described previously 24 . Two transfected lines, Has2-1 (Lanes 1 and 3) and Has2-2 (Lanes 2 and 4), are shown. Arrowheads, Has2. Weak bands around Mr 43,000 (*) are nonspecific bands reacting with secondary antibodies. B, overproduction of HA in Has2 transfectants. Cells were cultured in 35-mm wells, and total amounts of hyaluronan secreted into culture supernatants during a 24-h period were quantitated as described in "Materials and Methods." Columns, means of triplicate determinations; bars, SD.

	HA Production in Transfected Cells.

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS HA Production in Transfected... Adhesion and Growth in... Overproduction of HA Makes... HA Overproduction Increases... DISCUSSION REFERENCES

	Adhesion and Growth in Monolayers.

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS HA Production in Transfected... Adhesion and Growth in... Overproduction of HA Makes... HA Overproduction Increases... DISCUSSION REFERENCES

 
We first examined whether overproduction of HA affects adhesive properties of HT1080 cells. As shown in Fig. 2 , no significant differences were found with regard to the adhesion to fibronectin and type I collagen between Has2-transfectants and control cells. We have also examined the plating efficiency on tissue culture plastic using regular culture medium containing 10% FCS. We found no differences in plating efficiency between Has2-transfected and control transfected cells (data not shown). These results demonstrate that general adhesive properties of HT1080 cells are not affected by overproduction of HA.

View larger version (39K): [in this window] [in a new window] [Download PPT slide]   Fig. 2. Adhesion of Has2-transfectants to substrates of fibronectin (A) and type I collagen (B). Cell adhesion was quantitated by staining attached cells with toluidine blue as described in "Materials and Methods." Columns, means (n = 5) of A590 values; bars, SD.

View larger version (19K): [in this window] [in a new window] [Download PPT slide]   Fig. 3. Growth of Has2-transfected cells in monolayer cultures. Cells were plated in 35-mm wells in six-well tissue culture plates at 5 x 104 cells/well and cultured in growth medium. At time points indicated in the figure, duplicate wells were trypsinized, and cell numbers were counted using a hemacytometer.

	Overproduction of HA Makes Cells More Anchorage Independent.

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS HA Production in Transfected... Adhesion and Growth in... Overproduction of HA Makes... HA Overproduction Increases... DISCUSSION REFERENCES

View larger version (46K): [in this window] [in a new window] [Download PPT slide]   Fig. 4. Anchorage-independent growth of Has2-transfected cells in soft agar. A, Has2- and control-transfected cells were examined by the soft agar assay as described in "Materials and Methods." Dishes in triplicate were incubated at 37°C under 5% CO2, and the number of colonies consisting of more than 30 cells was determined for each dish at 10 days after plating. Columns, mean numbers of colonies; bars, SD. Experiments were repeated three times with similar results. B, phase contrast micrographs of colonies of Has2- and control-transfected cells in soft agar. Has2, Has2-transfected HT 1080 cells (clone Has2-1); Cont, control-transfected HT1080 cells (clone Cont-1).

View larger version (22K): [in this window] [in a new window] [Download PPT slide]   Fig. 5. Effects of chemical inhibition of HA synthesis on anchorage-independent growth of Has2-transfected cells. A, treatment with 0.1 mM MU reduces HA production. HA production was assayed as described above in the presence of 0.1 mM MU dissolved in 0.1% DMSO () or 0.1% DMSO alone (). B, treatment with 0.1 mM MU does not adversely affect the growth of cells in monolayers. Growth assay was performed in wells of 24-well tissue culture plates with Cont-1 cells in the presence of 0.05 mM and 0.1 mM MU in 0.1% DMSO or 0.1% DMSO alone. , 0.05 mM MU in 0.1% DMSO; , 0.1 mM MU in 0.1% DMSO; , 0.1% DMSO alone. C, enhanced anchorage independence of Has2-transfected cells was abolished by suppression of HA synthesis. Soft agar assays were performed in the presence of 0.1 mM MU in 0.1% DMSO () or 0.1% DMSO alone (). This result demonstrates that increased anchorage independence observed in Has2 transfectants is due to enzymatic activity of Has2 protein rather than to any unrelated activity of Has2 protein. Columns and data points, mean numbers of colonies in soft agar; bars, SD.

	HA Overproduction Increases Tumorigenicity in Vivo.

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS HA Production in Transfected... Adhesion and Growth in... Overproduction of HA Makes... HA Overproduction Increases... DISCUSSION REFERENCES

 
The in vitro assays described above suggest that tumorigenicity in vivo may also be promoted by HA overproduction. To examine this possibility, we performed tumorigenesis assays in nude mice. We found that Has2-transfected cells are more tumorigenic than control HT1080 clones (Fig. 6) . Has2-transfected cells grew more rapidly, and differences in tumor size between Has2 transfectants and control cells increased as tumor size increased (Fig. 6A) . By the termination of experiments, Has2 transfectants had formed tumors 3–4-fold larger than those derived from control cells (Fig. 6, B and C) .

View larger version (18K): [in this window] [in a new window] [Download PPT slide]   Fig. 6. Enhanced tumorigenicity of Has2-transfected cells. In vivo tumor growth assays in nude mice were performed as described in "Materials and Methods." A, time course of tumor growth. Growth of the tumors was evaluated by measuring tumor volume from the width and length of a palpable tumor as described in "Materials and Methods." Cells examined in this experiment were: , parental HT1080; •, Has2-1; , Has2-2. Data points, mean tumor volumes from four (parental HT1080) or five (Has2-1 and Has2-2) animals. B and C, tumor weights at termination of experiments. Results of two separate experiments (B and C) are shown. All animals involved in each experiment were sacrificed when the sign of distress was observed in any one animal in the experiment, which occurred at day 16 in B and day 13 in C. Columns, mean tumor weights per animal (i.e., the sum of tumor weights in both flanks) for each cell line; bars, SD. Numbers of animals examined were four for parental HT1080 and five for Has2-1 and Has2-2 in B and four for each cell line in C.

	DISCUSSION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS HA Production in Transfected... Adhesion and Growth in... Overproduction of HA Makes... HA Overproduction Increases... DISCUSSION REFERENCES

This study provides the first direct evidence that genetic manipulation of HA synthesis enhances the malignant phenotype of tumor cells. We found that increased HA synthesis promoted colony formation in soft agar and tumor formation in nude mice. The increased tumor size in nude mice from Has2-transfectants was due not to accumulation of tumor stroma or increased angiogenesis. Therefore, these results indicate that the cell-autonomous production of HA enhances proliferation of tumor cells.

The cellular origin of HA in tumors can be parenchymal cancer cells and/or stromal cells (11) . Although there is strong evidence that some cancer cells stimulate adjacent noncancerous stromal cells to produce HA (10 , 31) , a number of tumor cells have been shown to produce greater amounts of HA than their benign counterparts (11 , 21 , 22 , 32) . At present, it is not well understood how these different mechanisms are involved in tumor progression. Our results demonstrate that increased HA production by cancer cells has enhancing effects on the growth of tumors in vivo. Whether increased HA production by stromal cells has similar effects on the growth of tumors is not known. With HA synthase genes and their cDNAs available, this problem can now be tested by generating transgenic mouse models in which HA synthases are overexpressed in stromal cells. It is possible that cancer cell- and stromal cell-derived HA are involved in different aspects of malignant transformation.

There are several ways that high levels of HA might promote anchorage-independent growth and tumorigenesis of cells. For example, increased amounts of HA may facilitate cell division. It has been shown that HA synthesis occurs during cell division (33 , 34) , and it is thought that HA synthesis is important for cell detachment that occurs during cell division. It is also possible that an HA-rich environment may provide hydrated spaces that facilitate the migration of cells following mitosis. It has been suggested that high levels of HA within the ECM cause tissue spaces to become highly hydrated and to expand because of increased osmotic pressure (35) . This expanded and water-enriched environment is thought to deform the compact, restrictive architecture of extracellular matrices and facilitate cell movement (8 , 10) . Thus HA-overproducing tumor cells might migrate outwardly more efficiently, resulting in faster expansion of the tumor mass. Alternatively, HA-mediated cell signaling might be responsible for increased tumorigenicity. It has been reported that binding of HA to its cell surface receptors leads to activation of intracellular signaling pathways (36, 37, 38, 39, 40) . Notably, an HA receptor, RHAMM, has been shown to be involved in a signaling pathway leading to H-ras-mediated malignant transformation of fibroblastic cells (38) .

This work establishes that cell-autonomous overproduction of HA enhances transformation of tumor cells, although further study will be required to elucidate its mechanism. Because tumorigenicity in nude mice is the experimental parameter closely correlated with malignancy at the clinical level, it will be interesting to determine whether levels of cellular HA might also correlate with the level of clinical malignancy. A recent report by Ropponen et al. (12) on the correlation between tumor HA levels and the prognosis of patients with colorectal cancer appears to be consistent with this notion.

	ACKNOWLEDGMENTS

 
We thank Dr. Minoru Fukuda for critical reading of this manuscript.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by NIH Grants NS32717 and HD25938.

² Present address: Department of Geriatric Research, National Institute for Longevity Sciences, 36-3, Gengo, Morioka-cho, Ohbu 474, Aichi, Japan.

³ To whom requests for reprints should be addressed, at The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037. Phone: (619) 646-3124; Fax: (619) 646-3199; E-mail:yyamaguchi{at}:burnham-inst.org

⁴ The abbreviations used are: ECM, extracellular matrix; HA, hyaluronan; MU, 4-methylumbelliferone.

Received 9/ 2/98. Accepted 1/ 4/99.

	REFERENCES

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS HA Production in Transfected... Adhesion and Growth in... Overproduction of HA Makes... HA Overproduction Increases... DISCUSSION REFERENCES

 

1. Ruoslahti E., Yamaguchi Y. Proteoglycans as modulators of growth factor activities. Cell, 64: 867-869, 1991.[Medline]
2. Toole B. P. Developmental role of hyaluronate. Connect. Tissue Res., 10: 93-100, 1982.[Medline]
3. Turley E. A. Proteoglycans and cell adhesion: their putative role during tumorigenesis. Cancer Metastasis Rev., 3: 325-339, 1984.[Medline]
4. Turley E. A. Hyaluronan and cell locomotion. Cancer Metastasis Rev., 11: 21-30, 1992.[Medline]
5. Fraser J. R., Laurent T. C., Laurent U. B. Hyaluronan: its nature, distribution, functions and turnover. J. Int. Med., 242: 27-33, 1997.[Medline]
6. Laurent T. C., Fraser J. R. Hyaluronan. FASEB J., 6: 2397-2404, 1992.[Abstract]
7. Knudson C. B., Knudson W. Hyaluronan-binding proteins in development, tissue homeostasis, and disease. FASEB J., 7: 1233-1241, 1993.[Abstract]
8. Knudson W. Biswas, C., Li X. Q., Nemec R. E., Toole B. P. The role and regulation of tumour-associated hyaluronan. CIBA Found. Symp., 13: 150-159, 1989.
9. Rooney P., Kumar S., Ponting J., Wang M. The role of hyaluronan in tumor neovascularization (review). Int. J. Cancer, 60: 632-636, 1995.[Medline]
10. Knudson W. Tumor-associated hyaluronan. Providing an extracellular matrix that facilitates invasion. Am. J. Pathol., 148: 1721-1726, 1996.[Medline]
11. Delpech B., Girard N., Bertrand P., Courel M. N., Chauzy C., Delpech A. Hyaluronan: fundamental principles and applications in cancer. J. Int. Med., 242: 41-48, 1997.[Medline]
12. Ropponen K., Tammi M., Parkkinen J., Eskelinen M., Tammi R., Lipponen P., Ågren U., Alhava E., Kosma V-M. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res., 58: 342-347, 1998.[Abstract/Free Full Text]
13. Bertrand P., Girard N., Delpech B., Duval C., d’Anjou J., Dauce J. P. Hyaluronan (hyaluronic acid) and hyaluronectin in the extracellular matrix of human breast carcinomas: comparison between invasive and noninvasive areas. Int. J. Cancer, 52: 1-6, 1992.[Medline]
14. de la Torre M., Wells A. F., Bergh J., Lindgren A. Localization of hyaluronan in normal breast tissue, radial scar, and tubular breast carcinoma. Hum. Pathol., 24: 1294-1297, 1993.[Medline]
15. Auvinen P. K., Parkkinen J. J., Agren U. M., Johansson R. T., Tammi R. H., Eskelinen M. J., Kosma V-M. Expression of hyaluronan in benign and malignant breast lesions. Int. J. Cancer, 74: 477-481, 1997.[Medline]
16. Delpech B., Maingonnat C., Girard N., Chauzy C., Maunoury R., Olivier A., Tayot J., Creissard P. Hyaluronan and hyaluronectin in the extracellular matrix of human brain tumor stroma. Eur. J. Cancer, 29A: 1012-1017, 1993.
17. Horai T., Nakamura N., Tateishi R., Hattori S. Glycosaminoglycans in human lung cancer. Cancer (Phila.), 48: 2016-2021, 1981.[Medline]
18. Hopwood J. J., Dorfman A. Glycosaminoglycan synthesis by Wilm’s tumor. Pediatr. Res., 12: 52-56, 1978.[Medline]
19. Angello J. C., Hosick H. L., Anderson L. W. Glycosaminoglycan synthesis by a cell line (C1–S1) established from a preneoplastic mouse mammary outgrowth. Cancer Res., 42: 4975-4978, 1982.[Abstract/Free Full Text]
20. Angello J. C., Danielson K. G., Anderson L. W., Hosick H. L. Glycosaminoglycan synthesis by subpopulation of epithelial cells from a mammary adenocarcinoma. Cancer Res., 42: 2207-2210, 1982.[Abstract/Free Full Text]
21. Kimata K., Honma Y., Okayama M., Oguri K., Hozumi M., Suzuki S. Increased synthesis of hyaluronic acid by mouse mammary carcinoma cell variants with high metastatic potential. Cancer Res., 43: 1347-1354, 1983.[Abstract/Free Full Text]
22. Turley E. A., Tretiak M. Glycosaminoglycan production by murine melanoma variants in vivo and in vitro. Cancer Res., 45: 5098-5105, 1985.[Abstract/Free Full Text]
23. Zhang L., Underhill C. B., Chen L. Hyaluronan on the surface of tumor cells is correlated with metastatic behavior. Cancer Res., 55: 428-433, 1995.[Abstract/Free Full Text]
24. Watanabe K., Yamaguchi Y. Molecular identification of a putative human hyaluronan synthase. J. Biol. Chem., 271: 22945-22948, 1996.[Abstract/Free Full Text]
25. Euhus D. M., Hudd C., LaRegina M. C., Johnson F. E. Tumor measurement in the nude mouse. J. Surg. Oncol., 31: 229-234, 1986.[Medline]
26. Yamada H., Fredette B., Shitara K., Hagihara K., Miura R., Ranscht B., Stallcup W. B., Yamaguchi Y. J. . Neuroscience, 17: 7784-7795, 1997.[Abstract/Free Full Text]
27. Labarca C., Paigen K. A simple, rapid, and sensitive DNA assay procedure. Anal. Biochem., 102: 344-352, 1980.[Medline]
28. Wilson I. A., Niman H. L., Houghten R. A., Cherenson A. R., Connolly M. L., Lerner R. A. The structure of an antigenic determinant in a protein. Cell, 37: 767-778, 1984.[Medline]
29. Freedman V. H., Shin S. Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell, 3: 355-359, 1974.[Medline]
30. Nakamura T., Takagi K., Shibata S., Tanaka K., Higuchi T., Endo M. Hyaluronic acid-deficient extracellular matrix induced by addition of 4-methylumbelliferone to the medium of cultured human skin fibroblasts. Biochem. Biophys. Res. Commun., 208: 479-475, 1995.
31. Knudson W., Biswas C., Toole B. P. Interaction between human tumor cells and fibroblasts stimulate hyaluronate synthesis. Proc. Natl. Acad. Sci. USA, 81: 6767-6771, 1984.[Abstract/Free Full Text]
32. Hitzeman J., Woost P. G., Hosick H. L. Correlation of hyaluronic acid accumulation and the growth of preneoplastic mammary cells in collagen: a longitudinal study. In Vitro Cell Dev. Biol., 28A: 284-292, 1992.
33. Brecht M., Mayer U., Schlosser E., Prehm P. Increased hyaluronate synthesis is required for fibroblast detachment and mitosis. Biochem. J., 239: 445-450, 1986.[Medline]
34. Matuoka K., Namba M., Mitsui Y. Hyaluronate synthetase inhibition by normal and transformed human fibroblasts during growth reduction. J. Cell Biol., 104: 1105-1115, 1987.[Abstract/Free Full Text]
35. Laurent T. C., Laurent U. B., Fraser J. R. The structure and function of hyaluronan: an overview. Immunol. Cell Biol., 74: A1-A7, 1996.[Medline]
36. Bourguignon L. Y., Lokeshwar V. B., Chen X., Kerrick W. G. Hyaluronic acid-induced lymphocyte signal transduction and HA receptor (GP85/CD44)-cytoskeleton interaction. J. Immunol., 151: 6634-6644, 1993.[Abstract]
37. Guo Y. J., Ma J., Wong J. H., Lin S. C., Chang H. C., Bigby M., Sy M. S. Monoclonal anti-CD44 antibody acts in synergy with anti-CD2 but inhibits anti-CD3 or T cell receptor-mediated signaling in murine T cell hybridomas. Cell. Immunol., 152: 186-199, 1993.[Medline]
38. Hall C. L., Yang B., Yang X., Zhang S., Turley M., Samuel S., Lange L. A., Wang C., Curpen G. D., Savani R. C., Greenberg A. H., Turley E. A. Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell, 82: 19-28, 1995.[Medline]
39. Fraser S. P. Hyaluronan activates calcium-dependent chloride currents in Xenopus oocytes. FEBS Lett., 404: 56-60, 1997.[Medline]
40. Rafi A., Nagarkatti M., Nagarkatti P. S. Hyaluronate-CD44 interactions can induce murine B-cell activation. Blood, 89: 2901-2908, 1997.[Abstract/Free Full Text]

This article has been cited by other articles:

				A. Ghosh, H. Kuppusamy, and L. M. Pilarski Aberrant Splice Variants of HAS1 (Hyaluronan Synthase 1) Multimerize with and Modulate Normally Spliced HAS1 Protein: A POTENTIAL MECHANISM PROMOTING HUMAN CANCER J. Biol. Chem., July 10, 2009; 284(28): 18840 - 18850. [Abstract] [Full Text] [PDF]

				J. Webber, R. H. Jenkins, S. Meran, A. Phillips, and R. Steadman Modulation of TGF{beta}1-Dependent Myofibroblast Differentiation by Hyaluronan Am. J. Pathol., July 1, 2009; 175(1): 148 - 160. [Abstract] [Full Text] [PDF]

				D. Vigetti, M. Rizzi, M. Viola, E. Karousou, A. Genasetti, M. Clerici, B. Bartolini, V. C Hascall, G. De Luca, and A. Passi The effects of 4-methylumbelliferone on hyaluronan synthesis, MMP2 activity, proliferation, and motility of human aortic smooth muscle cells Glycobiology, May 1, 2009; 19(5): 537 - 546. [Abstract] [Full Text] [PDF]

				J. Webber, S. Meran, R. Steadman, and A. Phillips Hyaluronan Orchestrates Transforming Growth Factor-{beta}1-dependent Maintenance of Myofibroblast Phenotype J. Biol. Chem., April 3, 2009; 284(14): 9083 - 9092. [Abstract] [Full Text] [PDF]

				A. G. Bharadwaj, J. L. Kovar, E. Loughman, C. Elowsky, G. G. Oakley, and M. A. Simpson Spontaneous Metastasis of Prostate Cancer Is Promoted by Excess Hyaluronan Synthesis and Processing Am. J. Pathol., March 1, 2009; 174(3): 1027 - 1036. [Abstract] [Full Text] [PDF]

				Y. Miyake, M. Sakurai, S. Tanaka, W. A. S. Tunjung, M. Yokoo, H. Matsumoto, H. Aso, T. Yamaguchi, and E. Sato Expression of Hyaluronan Synthase 1 and Distribution of Hyaluronan During Follicular Atresia in Pig Ovaries Biol Reprod, February 1, 2009; 80(2): 249 - 257. [Abstract] [Full Text] [PDF]

				N. Itano Simple Primary Structure, Complex Turnover Regulation and Multiple Roles of Hyaluronan J. Biochem., August 1, 2008; 144(2): 131 - 137. [Abstract] [Full Text] [PDF]

				R. Hemming, D. C. Martin, E. Slominski, J. I. Nagy, A. J. Halayko, S. Pind, and B. Triggs-Raine Mouse Hyal3 encodes a 45- to 56-kDa glycoprotein whose overexpression increases hyaluronidase 1 activity in cultured cells Glycobiology, April 1, 2008; 18(4): 280 - 289. [Abstract] [Full Text] [PDF]

				N. Borg and M. Holland The effect of glycosaminoglycans on rat gametes in vitro and the associated signal pathway Reproduction, March 1, 2008; 135(3): 311 - 319. [Abstract] [Full Text] [PDF]

				S. Meran, D. Thomas, P. Stephens, J. Martin, T. Bowen, A. Phillips, and R. Steadman Involvement of Hyaluronan in Regulation of Fibroblast Phenotype J. Biol. Chem., August 31, 2007; 282(35): 25687 - 25697. [Abstract] [Full Text] [PDF]

				D. Manzanares, M.-E. Monzon, R. C. Savani, and M. Salathe Apical Oxidative Hyaluronan Degradation Stimulates Airway Ciliary Beating via RHAMM and RON Am. J. Respir. Cell Mol. Biol., August 1, 2007; 37(2): 160 - 168. [Abstract] [Full Text] [PDF]

				A. G. Bharadwaj, K. Rector, and M. A. Simpson Inducible Hyaluronan Production Reveals Differential Effects on Prostate Tumor Cell Growth and Tumor Angiogenesis J. Biol. Chem., July 13, 2007; 282(28): 20561 - 20572. [Abstract] [Full Text] [PDF]

				L. Y. W. Bourguignon, E. Gilad, and K. Peyrollier Heregulin-mediated ErbB2-ERK Signaling Activates Hyaluronan Synthases Leading to CD44-dependent Ovarian Tumor Cell Growth and Migration J. Biol. Chem., July 6, 2007; 282(27): 19426 - 19441. [Abstract] [Full Text] [PDF]

				C. Ricciardelli, D. L. Russell, M. P. Ween, K. Mayne, S. Suwiwat, S. Byers, V. R. Marshall, W. D. Tilley, and D. J. Horsfall Formation of Hyaluronan- and Versican-rich Pericellular Matrix by Prostate Cancer Cells Promotes Cell Motility J. Biol. Chem., April 6, 2007; 282(14): 10814 - 10825. [Abstract] [Full Text] [PDF]

				H. Koyama, T. Hibi, Z. Isogai, M. Yoneda, M. Fujimori, J. Amano, M. Kawakubo, R. Kannagi, K. Kimata, S. Taniguchi, et al. Hyperproduction of Hyaluronan in Neu-Induced Mammary Tumor Accelerates Angiogenesis through Stromal Cell Recruitment: Possible Involvement of Versican/PG-M Am. J. Pathol., March 1, 2007; 170(3): 1086 - 1099. [Abstract] [Full Text] [PDF]

				A. C. Cook, A. F. Chambers, E. A. Turley, and A. B. Tuck Osteopontin Induction of Hyaluronan Synthase 2 Expression Promotes Breast Cancer Malignancy J. Biol. Chem., August 25, 2006; 281(34): 24381 - 24389. [Abstract] [Full Text] [PDF]

				M. A. Simpson Concurrent Expression of Hyaluronan Biosynthetic and Processing Enzymes Promotes Growth and Vascularization of Prostate Tumors in Mice Am. J. Pathol., July 1, 2006; 169(1): 247 - 257. [Abstract] [Full Text] [PDF]

				A. Kultti, K. Rilla, R. Tiihonen, A. P. Spicer, R. H. Tammi, and M. I. Tammi Hyaluronan Synthesis Induces Microvillus-like Cell Surface Protrusions J. Biol. Chem., June 9, 2006; 281(23): 15821 - 15828. [Abstract] [Full Text] [PDF]

				J. I. Lopez, T. D. Camenisch, M. V. Stevens, B. J. Sands, J. McDonald, and J. A. Schroeder CD44 Attenuates Metastatic Invasion during Breast Cancer Progression Cancer Res., August 1, 2005; 65(15): 6755 - 6763. [Abstract] [Full Text] [PDF]

				L. Udabage, G. R. Brownlee, M. Waltham, T. Blick, E. C. Walker, P. Heldin, S. K. Nilsson, E. W. Thompson, and T. J. Brown Antisense-Mediated Suppression of Hyaluronan Synthase 2 Inhibits the Tumorigenesis and Progression of Breast Cancer Cancer Res., July 15, 2005; 65(14): 6139 - 6150. [Abstract] [Full Text] [PDF]

				M. Edward, C. Gillan, D. Micha, and R.H. Tammi Tumour regulation of fibroblast hyaluronan expression: a mechanism to facilitate tumour growth and invasion Carcinogenesis, July 1, 2005; 26(7): 1215 - 1223. [Abstract] [Full Text] [PDF]

				I. Kakizaki, K. Kojima, K. Takagaki, M. Endo, R. Kannagi, M. Ito, Y. Maruo, H. Sato, T. Yasuda, S. Mita, et al. A Novel Mechanism for the Inhibition of Hyaluronan Biosynthesis by 4-Methylumbelliferone J. Biol. Chem., August 6, 2004; 279(32): 33281 - 33289. [Abstract] [Full Text] [PDF]

				H.-R. Kim, M. A. Wheeler, C. M. Wilson, J. Iida, D. Eng, M. A. Simpson, J. B. McCarthy, and K. M. Bullard Hyaluronan Facilitates Invasion of Colon Carcinoma Cells in Vitro via Interaction with CD44 Cancer Res., July 1, 2004; 64(13): 4569 - 4576. [Abstract] [Full Text] [PDF]

				N. Itano, T. Sawai, F. Atsumi, O. Miyaishi, S. Taniguchi, R. Kannagi, M. Hamaguchi, and K. Kimata Selective Expression and Functional Characteristics of Three Mammalian Hyaluronan Synthases in Oncogenic Malignant Transformation J. Biol. Chem., April 30, 2004; 279(18): 18679 - 18687. [Abstract] [Full Text] [PDF]

				K. M. Stuhlmeier and C. Pollaschek Differential Effect of Transforming Growth Factor {beta} (TGF-{beta}) on the Genes Encoding Hyaluronan Synthases and Utilization of the p38 MAPK Pathway in TGF-{beta}-induced Hyaluronan Synthase 1 Activation J. Biol. Chem., March 5, 2004; 279(10): 8753 - 8760. [Abstract] [Full Text] [PDF]

				E. A. Marieb, A. Zoltan-Jones, R. Li, S. Misra, S. Ghatak, J. Cao, S. Zucker, and B. P. Toole Emmprin Promotes Anchorage-Independent Growth in Human Mammary Carcinoma Cells by Stimulating Hyaluronan Production Cancer Res., February 15, 2004; 64(4): 1229 - 1232. [Abstract] [Full Text] [PDF]

				J. Bakkers, C. Kramer, J. Pothof, N. E. M. Quaedvlieg, H. P. Spaink, and M. Hammerschmidt Has2 is required upstream of Rac1 to govern dorsal migration of lateral cells during zebrafish gastrulation Development, February 1, 2004; 131(3): 525 - 537. [Abstract] [Full Text] [PDF]

				K. M. Stuhlmeier and C. Pollaschek Glucocorticoids inhibit induced and non-induced mRNA accumulation of genes encoding hyaluronan synthases (HAS): hydrocortisone inhibits HAS1 activation by blocking the p38 mitogen-activated protein kinase signalling pathway Rheumatology, February 1, 2004; 43(2): 164 - 169. [Abstract] [Full Text] [PDF]

				A. Zoltan-Jones, L. Huang, S. Ghatak, and B. P. Toole Elevated Hyaluronan Production Induces Mesenchymal and Transformed Properties in Epithelial Cells J. Biol. Chem., November 14, 2003; 278(46): 45801 - 45810. [Abstract] [Full Text] [PDF]

				P. E. Pummill and P. L. DeAngelis Alteration of Polysaccharide Size Distribution of a Vertebrate Hyaluronan Synthase by Mutation J. Biol. Chem., May 23, 2003; 278(22): 19808 - 19814. [Abstract] [Full Text] [PDF]

				M. E. Mummert, D. I. Mummert, L. Ellinger, and A. Takashima Functional Roles of Hyaluronan in B16-F10 Melanoma Growth and Experimental Metastasis in Mice Mol. Cancer Ther., March 1, 2003; 2(3): 295 - 300. [Abstract] [Full Text] [PDF]

				A. E. Stock, N. Bouchard, K. Brown, A. P. Spicer, C. B. Underhill, M. Dore, and J. Sirois Induction of Hyaluronan Synthase 2 by Human Chorionic Gonadotropin in Mural Granulosa Cells of Equine Preovulatory Follicles Endocrinology, November 1, 2002; 143(11): 4375 - 4384. [Abstract] [Full Text] [PDF]

				S. Ghatak, S. Misra, and B. P. Toole Hyaluronan Oligosaccharides Inhibit Anchorage-independent Growth of Tumor Cells by Suppressing the Phosphoinositide 3-Kinase/Akt Cell Survival Pathway J. Biol. Chem., October 4, 2002; 277(41): 38013 - 38020. [Abstract] [Full Text] [PDF]

				K. Rilla, M. J. Lammi, R. Sironen, K. Torronen, M. Luukkonen, V. C. Hascall, R. J. Midura, M. Hyttinen, J. Pelkonen, M. Tammi, et al. Changed lamellipodial extension, adhesion plaques and migration in epidermal keratinocytes containing constitutively expressed sense and antisense hyaluronan synthase 2 (Has2) genes J. Cell Sci., September 15, 2002; 115(18): 3633 - 3643. [Abstract] [Full Text] [PDF]

				B. P. Toole and V. C. Hascall Hyaluronan and Tumor Growth Am. J. Pathol., September 1, 2002; 161(3): 745 - 747. [Full Text] [PDF]

				M. A. Simpson, C. M. Wilson, and J. B. McCarthy Inhibition of Prostate Tumor Cell Hyaluronan Synthesis Impairs Subcutaneous Growth and Vascularization in Immunocompromised Mice Am. J. Pathol., September 1, 2002; 161(3): 849 - 857. [Abstract] [Full Text] [PDF]

				Y. Zhang, A. A. Thant, K. Machida, Y. Ichigotani, Y. Naito, Y. Hiraiwa, T. Senga, Y. Sohara, S. Matsuda, and M. Hamaguchi Hyaluronan-CD44s Signaling Regulates Matrix Metalloproteinase-2 Secretion in a Human Lung Carcinoma Cell Line QG90 Cancer Res., July 15, 2002; 62(14): 3962 - 3965. [Abstract] [Full Text] [PDF]

				N. Itano, F. Atsumi, T. Sawai, Y. Yamada, O. Miyaishi, T. Senga, M. Hamaguchi, and K. Kimata Abnormal accumulation of hyaluronan matrix diminishes contact inhibition of cell growth and promotes cell migration PNAS, March 19, 2002; 99(6): 3609 - 3614. [Abstract] [Full Text] [PDF]

				M. A. Simpson, C. M. Wilson, L. T. Furcht, A. P. Spicer, T. R. Oegema Jr., and J. B. McCarthy Manipulation of Hyaluronan Synthase Expression in Prostate Adenocarcinoma Cells Alters Pericellular Matrix Retention and Adhesion to Bone Marrow Endothelial Cells J. Biol. Chem., March 15, 2002; 277(12): 10050 - 10057. [Abstract] [Full Text] [PDF]

				B. P. Toole Hyaluronan promotes the malignant phenotype Glycobiology, March 1, 2002; 12(3): 37R - 42R. [Abstract] [Full Text] [PDF]

				M. I. Tammi, A. J. Day, and E. A. Turley Hyaluronan and Homeostasis: A Balancing Act J. Biol. Chem., February 8, 2002; 277(7): 4581 - 4584. [Full Text] [PDF]

				B. P. Toole, T. N. Wight, and M. I. Tammi Hyaluronan-Cell Interactions in Cancer and Vascular Disease J. Biol. Chem., February 8, 2002; 277(7): 4593 - 4596. [Full Text] [PDF]

				C. L. Nutt, C. A. Zerillo, G. M. Kelly, and S. Hockfield Brain Enriched Hyaluronan Binding (BEHAB)/Brevican Increases Aggressiveness of CNS-1 Gliomas in Lewis Rats Cancer Res., October 1, 2001; 61(19): 7056 - 7059. [Abstract] [Full Text] [PDF]

				N. Liu, F. Gao, Z. Han, X. Xu, C. B. Underhill, and L. Zhang Hyaluronan Synthase 3 Overexpression Promotes the Growth of TSU Prostate Cancer Cells Cancer Res., July 1, 2001; 61(13): 5207 - 5214. [Abstract] [Full Text] [PDF]

				Y. Sohara, N. Ishiguro, K. Machida, H. Kurata, A. A. Thant, T. Senga, S. Matsuda, K. Kimata, H. Iwata, and M. Hamaguchi Hyaluronan Activates Cell Motility of v-Src-transformed Cells via Ras-Mitogen-activated Protein Kinase and Phosphoinositide 3-Kinase-Akt in a Tumor-specific Manner Mol. Biol. Cell, June 1, 2001; 12(6): 1859 - 1868. [Abstract] [Full Text] [PDF]

				J. M. Karjalainen, R. H. Tammi, M. I. Tammi, M. J. Eskelinen, U. M. Agren, J. J. Parkkinen, E. M. Alhava, and V.-M. Kosma Reduced Level of CD44 and Hyaluronan Associated with Unfavorable Prognosis in Clinical Stage I Cutaneous Melanoma Am. J. Pathol., September 1, 2000; 157(3): 957 - 965. [Abstract] [Full Text] [PDF]

				R. M. Peterson, Q. Yu, I. Stamenkovic, and B. P. Toole Perturbation of Hyaluronan Interactions by Soluble CD44 Inhibits Growth of Murine Mammary Carcinoma Cells in Ascites Am. J. Pathol., June 1, 2000; 156(6): 2159 - 2167. [Abstract] [Full Text] [PDF]

				M. A. Anttila, R. H. Tammi, M. I. Tammi, K. J. Syrjänen, S. V. Saarikoski, and V.-M. Kosma High Levels of Stromal Hyaluronan Predict Poor Disease Outcome in Epithelial Ovarian Cancer Cancer Res., January 1, 2000; 60(1): 150 - 155. [Abstract] [Full Text]

				L. Huang, N. Grammatikakis, M. Yoneda, S. D. Banerjee, and B. P. Toole Molecular Characterization of a Novel Intracellular Hyaluronan-binding Protein J. Biol. Chem., September 15, 2000; 275(38): 29829 - 29839. [Abstract] [Full Text] [PDF]

				M. A. Simpson, J. Reiland, S. R. Burger, L. T. Furcht, A. P. Spicer, T. R. Oegema Jr., and J. B. McCarthy Hyaluronan Synthase Elevation in Metastatic Prostate Carcinoma Cells Correlates with Hyaluronan Surface Retention, a Prerequisite for Rapid Adhesion to Bone Marrow Endothelial Cells J. Biol. Chem., May 18, 2001; 276(21): 17949 - 17957. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kosaki, R. Articles by Yamaguchi, Y. Search for Related Content PubMed PubMed Citation Articles by Kosaki, R. Articles by Yamaguchi, Y.